ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics reported positive topline data from the Phase 3 LOTIS-5 trial, where ZYNLONTA plus rituximab met the primary endpoint of progression-free survival (HR 0.73, p=0.008) versus R-GemOx in relapsed/refractory DLBCL. The combination also showed superior complete response rates (39.5% vs 26.7%) and duration of response, with no detrimental effect on overall survival (HR 0.96).
Key figures
- Drug Name
- ZYNLONTA (loncastuximab tesirine-lpyl)
- Phase Of Trial
- Phase 3
- Pfs p value
- 0.008
- Os hazard ratio
- 0.96
- Orr test arm pct
- 58.1
- Pfs hazard ratio
- 0.73
- Sae test arm pct
- 49
- Orr control arm pct
- 45.2
- Sae control arm pct
- 34.5
- Cr rate test arm pct
- 39.5
- Cr rate control arm pct
- 26.7
- Grade 5 teae test arm pct
- 13.2
- Median dor test arm months
- 9.2
- Median pfs test arm months
- 6.1
- Median docr test arm months
- 16.8
- Grade 5 teae control arm pct
- 4.6
- Teae withdrawal test arm pct
- 25.5
- Median dor control arm months
- 7.7
- Median pfs control arm months
- 4.7
- Median docr control arm months
- 12.3
- Teae withdrawal control arm pct
- 9.1
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.